Brief: Biomea Fusion Announces Approval Of “Icovamenib” As International Nonproprietary Name For Bmf-219
21/10/2024 16:26
Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION ANNOUNCES APPROVAL OF “ICOVAMENIB” AS
INTERNATIONAL NONPROPRIETARY NAME FOR BMF-219
Source text for Eikon: ID:nGNX8y6yQM
Further company coverage: BMEA.O
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes